Parabilis Medicines, Inc. (NASDAQ: PBLS) is a Healthcare company (Biotechnology) with a market capitalization of $3.4B. The Maz Rating grades it against the other companies in its sector.
Parabilis Medicines, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $28.25, Parabilis Medicines, Inc. trades at 1509.0x sales and 3.4x book value. Over the last twelve months it generated about $2M of revenue and a net loss of $229M. It runs a gross margin of -20.8%, an operating margin of -8381.7% and a net margin of -7828.5%. It shows return on equity of -23.1%, return on invested capital of -17.7% and a free cash flow yield of -3.7%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 12.88. Over the past 52 weeks the share price ranged from $20.00 to $42.49, with a beta of 5.03.
Parabilis Medicines, Inc. does not currently pay a dividend.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.